Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials

@article{Frankenstein2019RelativeEO,
  title={Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials},
  author={Lutz Frankenstein and Svenja E Seide and Tobias T{\"a}ger and Katrin Jensen and Hanna Fr{\"o}hlich and Andrew L Clark and Mirjam Seiz and Hugo A. Katus and Paul Nee and Lorenz Uhlmann and Huseyin Naci and Dan Atar},
  journal={Heart Failure Reviews},
  year={2019},
  volume={25},
  pages={161-171}
}
This study aims to assess the comparative benefit and risk profile of treatment with mineralocorticoid receptor antagonists (MRAs) with regard to all-cause mortality (primary endpoint), cardiovascular mortality, or heart failure (HF)–related hospitalization (secondary endpoints) and the safety endpoints hyperkalemia, acute renal failure, and gynecomastia in patients with chronic HF. We conducted a systematic review and network meta-analysis following PRISMA-P and PRISMA-NMA guidelines. From 16… 
Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives
TLDR
In 2017, the FDA approved a liquid suspension formulation of spironolactone, CaroSpir®, which will enable more heart failure and other patients in need of aldosterone inhibition to avail themselves of the protective and beneficial effects of sp ironolactones.
A retrospective study on the short-term effect of high-dose spironolactone (80 mg/d) on chronic congestive heart failure
TLDR
80 mg spironolactone can rapidly reduce BNP and NT-pro BNP concentration, enhance exercise tolerance, improve clinical signs and cardiac function classification, and has better efficacy.
Mineralocorticoid receptor antagonists in heart failure patients with chronic kidney disease: why, when, and how?
TLDR
The role of aldosterone inCHF, as well as timing, selection, and management of MRAs in CHF patients with CKD, are focused on.
The role of the mineralocorticoid receptor and mineralocorticoid-receptor-directed therapies in heart failure.
TLDR
The origins and the development of MRA are discussed and how their use has evolved from the 'potassium-sparing diuretics' spironolactone and canrenone over 60 years ago, to the more receptor-selective eplerenone and most recently the emergence of new non-steroidal receptor antagonists esaxerenone and finerenone.
VHRM_A_210150 571..579
TLDR
In 2017, the FDA approved a liquid suspension formulation of spironolactone, CaroSpir, which will enable more heart failure and other patients in need of aldosterone inhibition to avail themselves of the protective and beneficial effects of sp ironolactones.
Adding Insult to Injury: Are There Treatments for Myocardial Injury and Type 2 Myocardial Infarction?
  • H. White
  • Medicine, Biology
    Journal of the American Heart Association
  • 2020
TLDR
The Fourth Universal Definition of Myocardial Infarction described a plethora of pathophysiologic processes associated with myocardial injury, which was defined by elevation of cardiac troponin (cTn) levels >99th percentile of the normal reference range.

References

SHOWING 1-10 OF 52 REFERENCES
Eplerenone in patients with systolic heart failure and mild symptoms.
TLDR
Eplerenone, as compared with placebo, reduced both the risk of death and therisk of hospitalization among patients with systolic heart failure and mild symptoms.
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
TLDR
Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.
Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study
TLDR
In CHF outpatients, it was unable to observe an association between the use of spironolactone and improved survival when administered in addition to a combination of ACE/ARB and beta-blockers.
Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials.
TLDR
A 20% reduction in all-cause mortality was demonstrated with the use of aldosterone blockade in a clinically heterogeneous group of clinical trial participants with heart failure and post-MI.
Effects of Mineralocorticoid Receptor Antagonists on the Risk of Sudden Cardiac Death in Patients With Left Ventricular Systolic Dysfunction: A Meta-analysis of Randomized Controlled Trials
TLDR
Comparative effectiveness studies of MRAs on SCD in usual care as well as studies evaluating the efficacy of other therapies to preventSCD in patients receiving optimal MRA therapy are needed to guide clinical decision-making.
Effects of spironolactone and metoprolol on QT dispersion in heart failure.
TLDR
The addition of spironolactone or metoprolol to a conventional treatment in heart failure patients resulted in improved clinical conditions and the significant decrease in sudden death predictors corrected QT dispersion.
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
TLDR
The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis
TLDR
Data from the most extensively studied population, individuals with diabetes, do not support a long-term glycemic impact in these patients and further prospective studies are necessary to establish spironolactone's true biological effects and their clinical implications.
...
...